<DOC>
	<DOCNO>NCT00072644</DOCNO>
	<brief_summary>This study evaluate impact HIV protease inhibitor ritonavir pharmacokinetics-that , interaction medication body-of prednisolone prednisone give healthy volunteer . Prednisone , agent know corticosteroid , steroid hormone , convert body prednisolone . Ritonavir HIV medication fight virus block ability reproduce . Sometimes increase blood level drug give time , possible ritonavir increase blood level prednisolone medication . Results study provide information whether prednisone ritonavir interact potentially harmful way . The MDR1 genotype , , part person 's genetic constitution , may influence prednisolone behaves . Patients 18 50 year age good health , HIV , smoke may eligible study . There 10 participant another 5 later control subject . Those control group take prednisone , ritonavir . Participants undergo follow test procedure : - Medical history physical examination . - Collection blood urine assess general health . - Collection blood examine marker white blood cell determine kind MDR1 gene inherit . - HIV test . The screening visit take 3 4 hour , study take 28 49 day . For 3 study day , participant remain clinic 12 hour , On Study Day 1 , patient ask eat drink anything besides water come clinic . Blood sample collect measure prednisolone concentration well osteocalcin , blood protein involve bone formation . Blood test also allow look surface white blood cell . Patients receive breakfast along 20 mg prednisone . Urine sample collect also . Then patient dismiss asked collect urine sample return follow morning , Study Day 2 . At time additional blood collection . Patients begin take ritonavir 7 28 day first dose prednisone , dose 200 mg ( two 100 mg capsule ) twice daily food , continue 15 day . On 4th 14th day take ritonavir , patient ask visit clinic morning blood measure ritonavir blood take single 20-mg dose prednisone along ritonavir . Both medication take breakfast . Blood urine level prednisolone also measure . On 15th day ritonavir dosing , another blood collection routine lab test , well study blood cell osteocalcin .</brief_summary>
	<brief_title>Pharmacokinetic Interactions With Prednisolone Healthy Volunteers HIV-infected Patients Receiving Single-Dose Prednisone</brief_title>
	<detailed_description>Corticosteroid administration associate variety toxicity , include osteonecrosis Cushing 's Syndrome , patient HIV infection . The prevalence toxicity lead speculation protease inhibitor impair cytochrome P450 ( CYP ) 3A4-mediated metabolism corticosteroid lead increase systemic exposure toxicity . Conversely , reduce corticosteroid exposure may expect drug coadministrated CYP3A4 inducer non-nucleoside reverse transcriptase inhibitor ( NNRTI ) efavirenz . Despite hypothesized interaction antiretroviral medication corticosteroid , drug interaction agent class formally investigate . The objective study ( 1 ) determine impact HIV protease inhibitor ritonavir pharmacokinetics prednisolone administration oral prednisone healthy volunteer ( 2 ) determine respective influence chronic dose lopinavir-ritonavir ( LPV/r ) efavirenz ( EFV ) prednisolone pharmacokinetics HIV+ individual take single dose prednisone . For HIV-negative healthy volunteer portion study , 10 HIV-negative study subject receive single 20 mg dose prednisone , 3 14 day ritonavir exposure 200 mg twice daily . Blood urine collect 24 hr prednisone administration determine prednisolone pharmacokinetics renal elimination . Blood also collect determination MDR1 genotype , may influence prednisolone disposition . For portion study conduct HIV-infected volunteer , 3 group 10 subject recruit receive single 20 mg dose prednisone follow serial blood sample prednisolone concentration . The 3 group consist ( 1 ) individual receive HIV treatment regimen ( least 30 day ) include LPV/r ( 2 ) individual receive HIV treatment regimen ( least 30 day ) include EFV ( 3 ) individual receive antiretroviral treatment treatment devoid HIV protease inhibitor NNRTIs . Prednisolone concentration determine validated high performance chromatographic method . Non-compartmental method use characterize prednisolone pharmacokinetics study group . Pharmacokinetic parameter value compare use ANOVA post-hoc testing . Geometric mean data 90 % confidence interval report . This study characterize , first time , influence antiretroviral medication pharmacokinetics corticosteroid medication ( prednisolone ) .</detailed_description>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>INCLUSION CRITERIA : HIVnegative Healthy Subjects : 1 . Males female age 18 50 year . 2 . Healthy medical history physical exam 3 . Laboratory value within establish guideline participation clinical study : AST le equal 2 X ULN ; Serum creatinine less equal ULN ; hemoglobin great equal 11 g/dL . 4 . Ability abstain ingest grapefruit grapefruit juice study period . 5 . Negative serum pregnancy test female childbearing potential . 6 . Females childbearing potential able willing practice abstinence use nonhormonal effective method birth control study . 7 . Nonsmoker least 6 week prior study participation . HIVinfected Volunteers : 1 . HIVinfected male female age 18 50 year . 2 . Patients receive stable ARV regimen least 30 day include ( 1 ) LPV/r , ( 2 ) EFV , ( 3 ) ARV treatment treatment contain protease inhibitor , NNRTIs , medication know suspected alter prednisolone pharmacokinetics . 3 . Patients adequately control HIV disease laboratory physical exam ( HIVRNA le 50,000 copies/mL , CD4+ count great 200 cells/mm ( 3 ) , evidence active opportunistic infection pneumocystis infection , mycobacterial infection etc . ) 4 . Laboratory value within establish guideline participation clinical study : AST le equal 2X ULN ; hemoglobin great equal 11 g/dL . 5 . Ability abstain ingest grapefruit grapefruit juice 3 day ( 2 day , day prednisone administration ) . 6 . Negative serum pregnancy test female childbearing potential . 7 . Females childbearing potential able willing practice abstinence use non hormonal effective method birth control study . EXCLUSION CRITERIA : HIVnegative Healthy Subjects : 1 . Concomitant routine therapy prescription , overthecounter , herbal , holistic medication , include oral contraceptive 30 day prior study participation . Subjects must oral contraceptive least 30 day prior study day 1 . Intermittent ( PRN ) use acetaminophen nonsteroidal antiinflammatory medication ( i.e . ibuprofen ) allow study ; medication take day prednisone administration ( study day 1 , 10 , 20 ) . Subjects allowed take multivitamin mineral , equivalent , daily desire . 2 . Inability obtain venous access sample collection . 3 . Presence Diabetes Mellitus , Human immunodeficiency virus ( HIV ) infection , active tuberculosis , cardiac disease ( hypertension ; congestive heart failure etc . ) , renal disease ( chronic acute renal failure insufficiency ) , thyroid disease , hepatitis , osteoporosis , osteonecrosis , respiratory disease ( asthma require chronic treatment ; chronic obstructive pulmonary disease ) , myasthenia gravis , glaucoma , peptic ulcer disease require treatment , history psychiatric illness ( mild depression anxiety ) condition may interfere interpretation study result best interest subject opinion investigator . 4 . Clinical evidence adrenal insufficiency , Cushing 's Syndrome endocrine disease . 5 . Any clinical laboratory evidence active infection ( persistent fever , night sweat , nausea , vomit , diarrhea , chronic cough , WBC great upper limit normal . ) 6 . Vaccination within 30 day study day 1 . 7 . Exposure viral illness chicken pox measles within 30 day study participation . 8 . Positive pregnancy test breastfeed female . 9 . The presence persistent diarrhea malabsorption would interfere subject 's ability absorb drug . 10 . Drug alcohol use may impair safety adherence . 11 . History intolerance allergic reaction ( rash ; hive ; swell lip ; difficulty breathe ) corticosteroid medication ( e.g . prednisone ; prednisolone ; methylprednisolone ; dexamethasone etc . ) protease inhibitor ( ritonavir ; lopinavir ; amprenavir ; indinavir ; nelfinavir ; saquinavir ; atazanavir ) . 12 . Inability unwillingness female childbearing potential use nonhormonal ( barrier ) method contraception throughout study ( e.g . condom ; diaphragm etc. ) . 13 . Nonfasting total cholesterol triglyceride great equal 270 mg/dL . HIVinfected Volunteers : 1 . Concomitant routine therapy prescription ( include hormonal contraceptive ) , overthecounter , herbal , holistic medication know suspected alter prednisolone pharmacokinetics . Subjects must oral contraceptive least 30 day prior study day 1 . Intermittent ( PRN ) use acetaminophen nonsteroidal antiinflammatory medication ( i.e . ibuprofen ) allow study vitamin + mineral supplementation . 2 . Inability obtain venous access sample collection . 3 . Patients take ARV regimens consistent study 's inclusion criterion ; include patient take LPV combination EFV nevirapine . 4 . Laboratory and/or physical evidence active opportunistic infection . 5 . Diabetes Mellitus require treatment oral medication insulin , active tuberculosis , cardiac disease ( uncontrolled hypertension and/or congestive heart failure etc . ) , renal disease ( chronic acute renal failure insufficiency result baseline serum creatinine great 1.5 X upper limit normal ) , untreated/uncontrolled thyroid disease , active hepatitis , respiratory disease ( asthma require chronic treatment ; chronic obstructive pulmonary disease ) , myasthenia gravis , glaucoma , peptic ulcer disease require treatment , history psychiatric illness ( mild depression anxiety ) condition may interfere interpretation study result best interest subject opinion investigator . 6 . Clinical evidence adrenal insufficiency , Cushing 's Syndrome endocrine disease . 7 . Any clinical laboratory evidence active infection ( persistent fever , night sweat , nausea , vomit , diarrhea , chronic cough , WBC great upper limit normal . ) 8 . Vaccination within 30 day study day 1 . 9 . Exposure viral illness chicken pox measles within 30 day study participation . 10 . Positive pregnancy test breastfeed female . 11 . The presence persistent diarrhea malabsorption would interfere subject 's ability absorb drug . 12 . Drug alcohol use may impair safety adherence . 13 . History intolerance allergic reaction ( rash ; hive ; swell lip ; difficulty breathe ) corticosteroid medication ( e.g . prednisone ; prednisolone ; methylprednisolone ; dexamethasone etc. ) . 14 . Inability unwillingness female childbearing potential use nonhormonal ( barrier ) method contraception throughout study ( e.g . condom ; diaphragm etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 17, 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>Osteonecrosis</keyword>
	<keyword>Drug Interaction</keyword>
	<keyword>P-Glycoprotein</keyword>
	<keyword>Cytochrome P 450</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>